Understanding OUR Cytokine-Based Immunotherapy Candidates Our Dedication extends to advancing a robust portfolio of programs targeted at growing the horizons of cytokine-based immunotherapy, specifically for cancers where treatment options remain limited. Make use of the links below to learn a lot more about our portfolio of cytokine-based immunotherapy candidates. https://financefeeds.com/swissquote-sets-ambitious-2028-pre-tax-profit-target-chf-500-million/